Melanoma - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Melanoma - Pipeline Review, H2 2013 market report to its offering
Melanoma - Pipeline Review, H2 2013


, 'Melanoma - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Melanoma. Melanoma - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Melanoma.
- A review of the Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Melanoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Melanoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Johnson & Johnson
Vical Incorporated
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Nektar Therapeutics
Antigenics, Inc.
Inovio Biomedical Corporation
medac GmbH
Merck & Co., Inc.
Lentigen Corporation
Generex Biotechnology Corporation
Plexxikon Inc.
Amorfix Life Sciences Ltd.
Prolexys Pharmaceuticals, Inc.
Aposense Ltd.
Histogen, Inc.
ZIOPHARM Oncology, Inc.
Novartis AG
Aphios Corporation
Daewoong Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
SuperGen, Inc.
Teva Pharmaceutical Industries Limited
Hadasit Medical Research Services & Development Ltd
Exelixis, Inc.
Aduro BioTech
Alfacell Corporation
Bayer AG
MannKind Corporation
EpiCept Corporation
Hana Biosciences, Inc.
Celldex Therapeutics, Inc.
Anavex Life Sciences Corp.
Lorus Therapeutics Inc
Cleveland BioLabs, Inc.
Oncolytics Biotech Inc.
Compugen Ltd.
Patrys Limited
Curis, Inc.
La Jolla Pharmaceutical Company
Green Cross Corporation
Innocell Corporation
Synta Pharmaceuticals Corp.
Summit Corporation plc
Scancell Holdings Plc
MabVax Therapeutics, Inc.
Antigen Express, Inc.
Cancer Research Technology Limited
Digna Biotech, S.L.
PCI Biotech Holding ASA
Antisense Pharma GmbH
Bionucleon Srl
Ambit Biosciences Corporation
Philogen S.p.A.
Multimmune GmbH
Alethia Biotherapeutics Inc.
Hawthorn Pharmaceuticals, Inc.
MacroGenics, Inc.
PDS Biotechnology Corporation
AlphaVax, Inc.
Azaya Therapeutics, Inc.
Iconic Therapeutics, Inc.
ProNAi Therapeutics, Inc.
Jennerex Biotherapeutics, Inc.
Axelar AB
Pharminox Limited
Innogene Kalbiotech Pte Ltd.
NovaLead Pharma Pvt. Ltd.
Welichem Biotech Inc.
Vaccinogen, Inc.
APEIRON Biologics AG
NewLink Genetics Corporation
SBI Biotech Co., Ltd.
InteRNA Technologies B.V.
Cellceutix Corporation
Avir Green Hills Biotechnology AG
TVAX Biomedical, LLC
Genelux Corporation
Nereus Pharmaceuticals, Inc.
Viventia Biotechnologies Inc.
Lytix Biopharma AS
Medisyn Technologies, Inc.
ImmuneRegen BioSciences, Inc.
AIMM Therapeutics B.V.
Cancer Therapeutics CRC Pty Ltd
Targa Therapeutics Corp.
ImmunoFrontier, Inc.
Bioo Therapeutics
Pacific Northwest Biotechnology, LLC
PepTx, Inc.
Polaris Group
EyeGene, Inc.
ToleroTech Inc.
ISA Pharmaceuticals B.V.
Gradalis Inc.
SentoClone AB

To view the table of contents for this market research report please visit